Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fertifolin
- Development stage
- Phase 4
- Lead developer
- Valenta Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fertifolin is an oral dietary supplement developed by Valenta Pharmaceuticals, specifically formulated to support female reproductive health and fertility. It consists of a combination of myo-inositol and folic acid (Vitamin B9). Myo-inositol serves as a second messenger for insulin and follicle-stimulating hormone (FSH), helping to regulate glucose metabolism and improve oocyte quality, which is particularly beneficial for women with polycystic ovary syndrome (PCOS). Folic acid is a crucial nutrient for DNA synthesis and repair, and its supplementation is standard practice to prevent neural tube defects and support healthy fetal development during pregnancy. Fertifolin is typically used to prepare the body for conception and to support the early stages of pregnancy.
- Brand names
- Fertifolin
Beyond the preview
Go deeper on Fertifolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fertifolin.